Immunic Earnings Reports

Immunic, Inc. released its financial results for the quarter ended September 30, 2024, alongside a corporate update.

Immunic reported its Q1 2024 financial results, highlighting the advancement of its phase 2 CALLIPER trial and phase 3 ENSURE trials for vidofludimus calcium (IMU-838). The company also secured a private placement of up to $240 million, extending its cash runway into the third quarter of 2025.

Immunic reported its Q4 2023 financial results, emphasizing the successful three-tranche private placement of up to $240 million, which extends the company's cash runway into the third quarter of 2025. The company also highlighted positive interim data from its Phase 2 CALLIPER trial and the ongoing Phase 3 ENSURE program.

Immunic reported progress in the clinical development of vidofludimus calcium, including positive interim biomarker analysis from the phase 2 CALLIPER trial in progressive multiple sclerosis. The company's cash and cash equivalents were $59.7 million as of September 30, 2023, which is expected to fund operations into September 2024.

Immunic reported important clinical and preclinical data from its two lead pipeline programs, including vidofludimus calcium (IMU-838) and IMU-856. The company announced preclinical evidence showing vidofludimus calcium acts as a potent Nurr1 activator and reported positive results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease.

Immunic reported positive results from the Phase 1b clinical trial of IMU-856 in celiac disease, demonstrating improvements in histology, disease symptoms, biomarkers, and nutrient absorption. The company is preparing for a Phase 2b clinical trial of IMU-856 in celiac disease patients. Additionally, data from the maintenance phase of the Phase 2b CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis showed statistically significant activity compared to placebo. The company expects an interim biomarker analysis from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive MS in the second half of 2023.

Immunic reported its year end 2022 financial results, highlighting the progress of vidofludimus calcium for multiple sclerosis treatment and upcoming data readouts from clinical trials. The company's cash reserves are expected to fund operations into the fourth quarter of 2024.

Immunic reported its Q3 2022 financial results, highlighting a cash and cash equivalents balance of $72.8 million as of September 30, 2022, and a subsequent $56.4 million net cash raise in October 2022, expected to fund the company into the fourth quarter of 2024. The company is progressing the development of vidofludimus calcium (IMU-838) in multiple sclerosis (MS) and anticipates data from the first of its phase 3 ENSURE trials in relapsing MS by the end of 2025.

Immunic reported its second quarter 2022 financial results, highlighting progress in key clinical programs and setting the stage for important data readouts in the second half of the year. The company's cash and cash equivalents are expected to fund operations into the fourth quarter of 2023.

Immunic reported continued momentum in Q1 2022, both financially and within its clinical pipeline programs. They extended their cash runway into the third quarter of 2023 and are advancing their programs to achieve key value inflection points.

Immunic, Inc. reported its year-end 2021 financial results, highlighting clinical progress across key pipeline programs, including vidofludimus calcium (IMU-838) and IMU-935. Enrollment was initiated in the Phase 3 ENSURE program for relapsing multiple sclerosis, and positive results were reported from the Phase 1 clinical trial of IMU-935.

Immunic reported its third quarter 2021 financial results, highlighting the advancement of its clinical programs, including IMU-838 and IMU-935. The company's cash and cash equivalents totaled $110.4 million as of September 30, 2021, which is expected to fund operations into 2023.

Immunic reported progress with IMU-838 and IMU-935, with five data read-outs anticipated from clinical trials within the next twelve months and the initiation of the first phase 3 program. The company received FDA clearance for the phase 3 ENSURE program of IMU-838 and expects to complete recruitment of the phase 2 CALDOSE-1 trial. Immunic had $87.2 million in cash and cash equivalents as of June 30, 2021, and an additional $45.0 million was raised in July, expected to fund operations into 2023.

Immunic reported its Q1 2021 financial results, highlighting the confirmation of the 30 mg dose of IMU-838 as most appropriate for the planned Phase 3 program in relapsing-remitting multiple sclerosis and the securing of full rights to IMU-838 with the settlement of the remaining royalty obligation to 4SC AG for $17.25 million.

Immunic reported its year-end 2020 financial results, highlighting positive data from clinical trials of IMU-838 and a bolstered balance sheet with $127.5 million in cash and cash equivalents.

Immunic reported positive phase 2 data for IMU-838 in relapsing-remitting multiple sclerosis and is preparing end-of-phase 2 submission. They completed a successful common stock offering, raising $103.5 million. The company's cash position of approximately $133.2 million is expected to fund activities into the second half of 2022.

Immunic reported positive top-line data from its Phase 2 EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis, meeting primary and key secondary endpoints. The company also announced Q2 2020 financial results, including $48.6 million in cash and cash equivalents.

Immunic reported its Q1 2020 financial results, highlighting the potential of IMU-838 as a therapeutic for SARS-CoV-2 infections and a successful $15.0 million financing.

Immunic's 2019 was marked by the closing of a stock-for-stock exchange transaction and the completion of enrollment for the phase 2 EMPhASIS trial of IMU-838. The company anticipates reporting top-line results in the third quarter of 2020 and has cash of $29.4 million providing funding through key 2020 inflection points.